Evidence map›Paper›PMID 17451192›Full record

ReviewWorld journal of gastroenterology2007

Practical guidelines for the treatment of inflammatory bowel disease.

T Kuhbacher, U R Fölsch

Abstract readEditorialReview
In one paragraph

Review in World journal of gastroenterology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Association between TNF-alpha and Entamoeba histolytica diarrhea.The American journal of tropical medicine and hygiene · 2010
    Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

T Kuhbacher
U R Fölsch

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, great progress has been made regarding the treatment of inflammatory bowel disease (IBD), particularly in the field of biological therapies. Nevertheless, the ultimate treatment is not in sight. With the development of new medication, it has become clear that we need a new understanding of IBD. Therapy needs to fit the different subtypes of IBD; e.g. mild disease in comparison to severe chronic active disease or Crohn's disease with or without fistulation or stenosis. The following article gives a practical overview of actual treatments for IBD. The intention of this article is not to provide a complete review of all new scientific developments, but to give a practical guideline for therapy of IBD.

Indexed as

Adrenal Cortex HormonesAnti-Bacterial AgentsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAnti-Inflammatory AgentsAnti-Inflammatory Agents, Non-SteroidalFemaleHumansImmunosuppressive AgentsInflammatory Bowel DiseasesInterferon-betaNatalizumabPregnancyProbioticsTumor Necrosis Factor-alphaAdrenal Cortex HormonesAnti-Bacterial AgentsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAnti-Inflammatory AgentsAnti-Inflammatory Agents, Non-SteroidalImmunosuppressive AgentsInterferon-betaNatalizumabTumor Necrosis Factor-alpha

Identifiers

PMID17451192
PMCPMC4146986

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.